References
- StephensPHunterCBignellGLung cancer: intragenic ERBB2 kinase mutations in tumoursNature20044317008525526
- ShigematsuHTakahashiTNomuraMSomatic mutations of the HER2 kinase domain in lung adenocarcinomasCancer Res20056551642164615753357
- ArcilaMEChaftJENafaKPrevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomasClin Cancer Res201218184910491822761469
- KrisMGJohnsonBEBerryLDUsing multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsJAMA2014311191998200624846037
- SpectorNLBlackwellKLUnderstanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol200927345838584719884552
- PereraSALiDShimamuraTHER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapyProc Natl Acad Sci U S A2009106247447919122144
- MazièresJPetersSLepageBLung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJ Clin Oncol201331161997200323610105
- LiBTRossDSAisnerDLHER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung CancersJ Thorac Oncol201611341441926723242
- KrisMGCamidgeDRGiacconeGTargeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsAnn Oncol20152671421142725899785
- SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
- RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
- GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
- BlackwellKLBursteinHJStornioloAMOverall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 StudyJ Clin Oncol201230212585259222689807
- BaselgaJCortésJKimSBCLEOPATRA Study GroupPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
- GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
- GatzemeierUGrothGButtsCRandomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancerAnn Oncol2004151192714679114
- SolcaFDahlGZoephelATarget binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blockerJ Pharmacol Exp Ther2012343234235022888144
- LiHDurbinRFast and accurate short read alignment with Burrows-Wheeler transformBioinformatics200925141754176019451168
- McKennaAHannaMBanksEThe Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing dataGenome Res20102091297130320644199
- KoboldtDCZhangQLarsonDEVarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencingGenome Res201222356857622300766
- KosakaTTanizakiJParanalRMResponse Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsCancer Res201777102712272128363995
- LiCSunYFangRLung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gainsJ Thorac Oncol201271858922071781
- YoshizawaASumiyoshiSSonobeMHER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutationsLung Cancer201485337337825047676
- LiBTLeeAO’TooleSHER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinibLung Cancer201590361761926559459